Castle Biosciences (CSTL) Change in Receivables (2018 - 2026)

Castle Biosciences has disclosed Change in Receivables across 9 years of filings, most recently posting -$1.1 million for Q1 2026.

• Change in Receivables for Q1 2026 came in at -$1.1 million, down 120.61% year-over-year; the trailing twelve-month figure through Mar 2026 was -$13.2 million (down 196.84% YoY), and the FY2025 annual result was -$6.9 million, down 154.39% from the prior year.
• Change in Receivables came in at -$1.1 million for Q1 2026 at Castle Biosciences, up from -$6.3 million in the prior quarter.
• In the past five years, Change in Receivables ranged from a high of $5.8 million in Q3 2023 to a low of -$6.3 million in Q4 2025.
• The 5-year median for Change in Receivables is $2.7 million (2022), against an average of $1.5 million.
• Across the five-year window, Change in Receivables soared 11502.0% in 2023 and tumbled 915.6% in 2025, its largest moves.
• Castle Biosciences' Change in Receivables stood at $540000.0 in 2022, then surged by 113.15% to $1.2 million in 2023, then sank by 33.19% to $769000.0 in 2024, then sank by 915.6% to -$6.3 million in 2025, then surged by 82.86% to -$1.1 million in 2026.
• The last three Change in Receivables figures came in at -$1.1 million (Q1 2026), -$6.3 million (Q4 2025), and -$1.9 million (Q3 2025), per Business Quant data.